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r“Rheumatic fever licks the joints, . . . but it bites the heart.”
—Ernest-Charles Lasègue (1)
lthough infrequent in the developed world, rheumatic heart
isease (RHD) remains a major health problem worldwide,
nd with increasing immigration over the past decades, will
ontinue to be encountered in most cardiology practices. The
orld Health Organization has estimated that more than 15
illion people worldwide are affected, with a half million new
ases of acute rheumatic fever (ARF) yearly (2). These esti-
ates are most likely conservative given the inadequate access
o medical care in the populations most at risk for streptococcal
nfections. Moreover, the data on RHD are mostly based on
uscultatory evidence of valvular disease in those at risk for the
equelae of ARF, with many patients having occult valvular
nvolvement (3).
See page 1874
Although ARF is theoretically preventable through the use
f antibiotic treatment for streptococcal infections, once ARF
as occurred, there has been no proven therapy to prevent
rogression to valvular involvement beyond the prevention of
ecurrent episodes of ARF (recurrent ARF episodes are
hought to contribute to further valve damage). In this issue of
he Journal, Antonini-Canterin et al. (4) report on a possible
ew therapy to prevent progression of RHD, namely the use of
tatins. In a retrospective echocardiography-based study, the
nvestigators report that the progression of rheumatic aortic
alve disease, as assessed by peak aortic velocity, was signifi-
antly slower in the patients who received statin therapy.
pecifically the annual change in peak aortic velocity was 0.05
0.07 m/s/year versus 0.12  0.11 m/s/year (p  0.001) in
hose on statin therapy versus those not on statin therapy.
oreover, rapid progression (defined as an annual rate of0.1
/s) was found in almost one-half of the patients not receiving
Editorials published in the Journal of the American College of Cardiology reflect the
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merican College of Cardiology.
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en-Yehuda has received research grants from Merck & Co., and he is on the
peakers’ Bureau of Schering-Plough Pharmaceuticals.tatins but only in 10% of the statin-treated patients. Mean
ollow-up was 8.5 years, thereby providing relatively long-term
ata.
The study is innovative and important in that it high-
ights a potentially simple therapy, but also has significant
imitations. In assessing the clinical applicability of this data,
everal key questions need to be addressed. What is the
cientific rationale for statin therapy for RHD? What are
he possible limitations of this retrospective study? What
an we learn from similar retrospective studies with statins
n other disease states? Can this data be applied to patients
n the absence of a prospective randomized trial?
ARF is characterized by an abnormal immune response
o infection with rheumatogenic group A streptococci, and
uch progress has been made in understanding why certain
ndividuals are susceptible to ARF. Associations with cer-
ain human leukocyte antigen types, abnormal T-cell acti-
ation and infiltration, and the presence of B-cells with a
istinctive alloantigen (d8/17) have been identified in ARF
atients, along with genetic variations in tumor necrosis
actor alpha (reviewed by Bryant et al. [5]). The inflamma-
ion of ARF results in a characteristic histopathological
icture, including the presence of Aschoff bodies and
eukocyte infiltration. Although the pathognomonic Aschoff
odies are rarely seen in the valves themselves, ARF does
ead to an acute valvulitis with inflammation and edema of
he leaflets. Fibrin–platelet thrombi occur along the leaflet
ontact zones (6). Fibrosis of the affected valves leads to
eformity, stenosis, and insufficiency. The progression to
anifest RHD, particularly the calcification that accompa-
ies RHD, was until recently thought to be a passive process
ttributable to the abnormal hemodynamics caused by the
eformed valves. Recent studies, however, have highlighted
he presence of ongoing inflammation (7) (as evidenced by
igh C-reactive protein levels) and oxidative stress, as well
s the participation of T-lymphocytes and inflammatory
ytokines (8). Moreover, calcification fronts in explanted
alves have been shown to colocalize with vascular endo-
helial growth factor expression (suggestive of neoangiogen-
sis) and osteoblast-like bone formation (9). These data
uggest that progression of RHD is not a passive process but
ather the result of an organized inflammatory process. If
ndeed RHD is an inflammatory disease, then modulators of
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ression of disease.
Although statins were developed to lower blood choles-
erol levels and specifically low-density lipoprotein (LDL)
evels, it has been appreciated since the 1990s that statins
lso possess non–LDL-lowering effects (reviewed by Shaw
t al. [10]). Although the term pleotropism has been applied
o these additional effects, most are a direct result of the
ownstream effect of inhibiting 3-hydroxy-3-methylglutaryl
oenzyme A, the rate limiting enzyme in the synthesis of
holesterol. Specifically, by inhibiting mevalonic acid for-
ation, statins also decrease the formation of isoprenoid
ntermediaries that serve as important intracellular signal
olecules for the rho-associated coiled-coil containing pro-
ein kinase pathway. Mevalonic acid itself induces cellular
rowth and differentiation. Recent data suggest that for the
ame level of LDL reduction, higher-dose statins in com-
arison with a statin/ezetimibe combination result in a
reater reduction in rho-associated coiled-coil containing
rotein kinase activity and improved endothelial function,
ith similar effect on high-sensitivity C-reactive protein
11). Statins therefore are thought to possess anti-
nflammatory properties. There is thus a rationale for consid-
ring statin therapy for the inflammatory aspects of RHD.
The pleiotropic effects of statins have led to their pro-
osed use in various cardiovascular (heart failure, calcific
ortic stenosis, atrial fibrillation) and noncardiovascular
iseases (osteoporosis, Alzheimer disease). Almost invari-
bly the initial impetus has been retrospective studies similar
o the study by Antonini-Canterin et al. (4). Unfortunately,
arge-scale randomized trials have failed to confirm these
reliminary findings in either heart failure (12) or in calcific
ortic stenosis (13). The experience with osteoporosis has
een similar—a randomized trial (14) has failed to confirm
he findings of observational studies (15). The findings from
he SEAS (Simvastatin and Ezetimibe in Aortic Stenosis)
13) study of aortic stenosis are particularly relevant. Con-
rary to the findings of a previous small open-label study
16), there was no efficacy detected with the treatment of
imvastatin 40 mg/ezetimibe 10 mg on either clinical end
oints (need for aortic valve replacement) or echocardio-
raphic progression of disease. Although the pathologic
rocesses in calcific aortic stenosis and RHD are distinct,
nflammation is thought to participate in both. In this
egard, the disappointing experience in the SEAS trial
hould at least lead to caution in embracing the results of the
resent study in RHD.
What is the explanation for the disparate effects between
etrospective observational studies and randomized trials? One
ossibility is the phenomenon of prevention bias, a term coined
y Barrett-Connor (17) to highlight the finding that taking
ertain medications, such as hormone replacement therapy, or
n the present study statins, may be a marker for other
ealth-promoting behaviors. That still leaves unanswered how
hese unmeasured confounders are slowing the progression of
isease in the patients receiving statins.The study by Antonini-Canterin et al. (4) is also limited
o disease progression in the aortic valve, with no data on
rogression in the mitral valve because most of their patients
ad already had interventions on the mitral valve. The
itral valve is the more frequently involved valve in RHD
nd is often more severely affected.
Given the retrospective nature of the present study, the
esults, although potentially very important, can in a strict
ense be considered hypothesis generating only and in need
or further confirmation in a placebo-controlled trial. Is it
easonable to expect such a study? The SEAS trial required
,873 patients to be adequately powered for clinical end
oints. For echocardiographic end points, however, smaller
tudies would be adequately powered, as illustrated by the
ndings in this retrospective with only 164 patients. Given
he importance of the issue, it would be hoped that a
ulticenter international effort, perhaps led by the World
ealth Organization, be instituted to formally test the statin
ypothesis in a prospective placebo-controlled manner.
What should clinicians do in the interim? For some
atients, the presence of concomitant indications for statin
herapy makes the decision easy. For the rest, the decision to
nitiate treatment is more complex. Women have a higher
ncidence of progression to valvular RHD than men. Un-
ortunately, the progression of RHD is likely to occur
uring childbearing years for women. Statins are contrain-
icated in pregnancy and in women who are likely to
ecome pregnant. Therefore, this not-fully-proven option is
ot appropriate for many at risk of RHD.
eprint requests and correspondence: Dr. Ori Ben-Yehuda,
niversity of California, San Diego, 200 West Arbor Drive, San
iego, California 92103-8200. E-mail: obenyehuda@ucsd.edu.
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